• Explore /
  • Poster
  • / Anlotinib in combination with TQB2450 in patients with recurrent ovarian cancer (ACTION): A multicenter, single-arm, open-label, phase Ib trial.

Anlotinib in combination with TQB2450 in patients with recurrent ovarian cancer (ACTION): A multicenter, single-arm, open-label, phase Ib trial.

Abstract Poster

Authors

null

Chunyan Lan

Sun Yat-sen University Cancer Center, Guangzhou, China

Chunyan Lan , Jing Zhao , Fan Yang , Rong Li , Yu Huang , Jing Wang , Weihong Zhao , Li Zhang , Chang Liu , Xuehan Bi , Haihong Jin , Jin Meng , Xin Huang

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Ovarian Cancer

Clinical Trial Registration Number

NCT04236362

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 5557)

DOI

10.1200/JCO.2021.39.15_suppl.5557

Abstract #

5557

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Changying Guo

First Author: Brian M. Slomovitz

First Author: Andrea Grace Bocobo

First Author: Wei Li